Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,932,241

« Back to Dashboard
Patent 7,932,241 protects ZOMETA and RECLAST and is included in two NDAs. There have been zero Paragraph IV challenges on Zometa and Reclast There are twelve tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for RECLAST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-five patent family members in twenty-one countries.

Summary for Patent: 7,932,241

Title:Pharmaceutical products comprising bisphosphonates
Abstract: A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.
Inventor(s): Glausch; Alexandra (Weil am Rhein, DE), Loffler; Rolf (Freiburg, DE), Sigg; Juergen (Loerrach, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/570,339
Patent Claim Types:
see list of patent claims
Formulation; Compound; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 5th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
zoledronic acid
INJECTABLE;IV (INFUSION)021223-003Jun 17, 2011RXYes7,932,241Feb 5, 2028Y
zoledronic acid
INJECTABLE;IV (INFUSION)021817-001Apr 16, 2007RXYes7,932,241*PEDAug 5, 2028Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,932,241

PCT Information
PCT FiledSeptember 17, 2004PCT Application Number:PCT/EP2004/010470
PCT Publication Date:March 24, 2005PCT Publication Number: WO2005/025551

International Patent Family for Patent: 7,932,241

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2358739► subscribe
Russian Federation2006112596► subscribe
Peru04682005► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.